Sheet 1 of 2

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-31193A APPLICATION NO. 09/817,487 **APPLICANT** PIPPIG ET AL. **FILING DATE** MARCH 26, 2001

Group 1646

L	LS.	PΔ	TF	TL	DO	CU	IME	NTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD	***					
	AE						
	AF						
	AG						
	АН						
	Al						
•	AJ						
	AK					·	
	AL			<u> </u>			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
/	AM							
/	AN							
/	AO							
/	AP							
/	AQ							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

$ \downarrow$ \perp	AT	Marking," Gene Therapy, 6:1222-1230 (1999)	•
		Hildinger, et al., "Bicistronic Retroviral Vectors for Combining Myeloprotection with Cell-Surface	•
,	AS	International Search Report for PCT/EP01/03543, dated September 10, 2001 Considered; Do Not Print.	
RLi	AR	Glass, et al., "Kinase Domain of the Muscle-Specific Receptor Tyrosine Kinase (MuSK) is Suffi for Phosphorylation but not Clustering of Acetylcholine Receptors: Required Role for the MuSk Ectodomain?" <i>Proc. Natl. Acad. Sci. USA</i> , 94:8848-8853 (August 1997)	icient

EXAMINER

Rushiang L. DATE CONSIDERED 8/24/2002
Initial of reference considered, Whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if nec ssary)

ATTY. DOCKET NO. 4-31193A APPLICATION NO. 09/817,487 APPLICANT 說PPIG ET AL. **EILING DATE** MARCH 26, 2001

Group 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

RL:	AA	Zhou, et al., "Distinct Domains of MuSK Mediate Its Abilities to Induce and to Associate with Postsynaptic Specializations," <i>The Journal of Cell Biology</i> , 146(5):1133-1146 (September 6, 1999)
	АВ	
	AC	
-	AD	
	AE	
	AF	
	AG	
	АН	
	AI	
	AJ	
	AK	
	AL	
	АМ	
	AN	
EXAMINER		Ruidians & DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several Deets if neoccasary)

ATTY. DOCKET NO. 4-31193A APPLICATION NO. 09/817,487 **APPLICANT** PIPPIG ET AL. **FILING DATE** MARCH 26, 2001

Group 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
RLI	AA	5,521,295	5/28/96	Pacifici, et al.			11/8/94
RLi	AB	5,656,473	8/12/97	Valenzuela, et al.			1/19/95
	AC						
	AD						
	AE						
	AF						
	AG						
	АН						x ++
	Al						
	AJ						
	AK					, s.A.	
	AL					, et	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
RNI	AM	WO 95/06723 🕡 🗂	3/9/95	PCT				
RLi	AN	WO 98/19540 🎍 /	5/14/98	PCT				0-
	AO							
	AP							
	AQ							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Genbank AF006464
AS	Genbank NM005592
AT	Genbank U34985
EXAMINER	DATE CONSIDERED OF A STATE OF THE PROPERTY OF

flaghore

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

PUP Several sheets if necessary)

ATTY. DOCKET NO. 4-31193A APPLICATION NO. 09/817,487 **APPLICANT** PIPPIG ET AL. FILING DATE MARCH 26, 2001

Group

Sheet 2 f 2

1646

THADEN	ARA	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
RLi	AA	Glass, et al., "Agrin acts via a MuSK receptor complex," Cell, 85:513-523 (May 17, 1996)
	АВ	Hesser, et al., "Identification and characterization of a novel splice variant of MuSK," <u>FEB Letters</u> , 442:133-137 (1999)
	AC	Jolly, et al., "Isolation and characterization of a full-length expressible cDNA for human hypoxanthine phosphoribosyltransferase," Proc. Natl. Acad. Sci. USA , 80:477-481 (January 1983)
	AD	Kashles, et al., "A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization," Molecular and Cell Biology, 11(3):1454-1463 (March 1991)
	AE	Norris, et al., "High-titer MSCV-based retrovirus generated in the pCL acute virus packaging system confers sustained gene expression in vivo," <u>J. Virol. Methods</u> , 75:161-167 (1998)
	AF	Pawliuk, et al., "Sustained high-level reconstitution of the hematopoietic system by preselected hematopoietic cells expressing a transduced cell-surface antigen," <u>Human Gene Therapy</u> , 8:1595-1604 (September 1, 1997)
	AG	Persons, et al., "Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo," <u>Blood</u> , 90(5):1777-1786 (September 1, 1997)
	АН	Reddy, et al., "Transient expression of full-length and truncated forms of the human nerve growth factor receptor," Molecular Brain Research, 8:137-141 (1990)
	AI	Valenzuela, et al., "Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury," Neuron, 15:573-584 (September 1995)
V	AJ	van der Geer, et al., "Receptor protein-tyrosine kinases and their signal transduction pathways," <u>Annual Review of Cell Biology</u> , 10:251-337 (1994)
	AK	
	AL	
	АМ	
	AN	
EXAMINER	3 .	Ruding L. DATE CONSIDERED 8/24/2002

8/24/2002 *EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Includ a copy of this form with the next communication to applicant.